January 20, 2016

NextSource Biotechnology Gains FDA Approval for New 5mg Strength of Gleostine® (Lomustine), an Anti-Cancer Chemotherapy Agent

by adminin Press Release0 comments

MIAMI, January 20, 2016 (BUSINESS WIRE)– NextSource Biotechnology, LLC announced today that Gleostine® (lomustine) 5 mg capsules has been approved by the U.S. Food and Drug Administration (FDA) and is now commercially available in the United States. Gleostine® is approved for use as a single agent treatment or in combination with other approved chemotherapeutic agents. […] Read more

January 24, 2014

NextSource Biotechnology Announces FDA Short Supply release of the formally known Bristol Myers Squibb (CeeNu®) Brand Oncology product now currently marketed under the NextSource Biotechnology Lomustine (CCNU) label Exclusively in the United States

by adminin Press Release0 comments

MIAMI, Jan. 24, 2014 /PRNewswire/ — NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching “Matured & Orphan Drugs,” has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug […] Read more

September 23, 2013

NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand

by adminin Press Release0 comments

MIAMI, Sept. 23, 2013 /PRNewswire/ — NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a “Matured & Orphan Drugs” product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network as a key synergistic approach to aggressively build […] Read more